{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T23:44:33Z","timestamp":1786146273702,"version":"build-2736575974"},"reference-count":21,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017037","name":"Cepheid","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017037","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.clbc.2026.06.012","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T19:46:26Z","timestamp":1784922386000},"page":"112-120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Xpert Breast Cancer Insight Test Predicts Distant Recurrence and Overall Survival in ER-Positive, HER2-Negative Early Breast Cancer"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2847-4534","authenticated-orcid":false,"given":"Martin","family":"Filipits","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoria","family":"Gruber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian F.","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Fitzal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsanna","family":"Bago-Horvath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Greil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marija","family":"Balic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Regitnig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Toro-Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Hulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Egle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daneida","family":"Lizarraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Kaldate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malini","family":"Satya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodi","family":"Weidler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Hlauschek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Dubsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gnant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2026.06.012_bib0001","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1111\/febs.13354","article-title":"Delineating transcriptional networks of prognostic gene signatures refines treatment recommendations for lymph node-negative breast cancer patients","volume":"282","author":"Lanigan","year":"2015","journal-title":"FEBS J"},{"key":"10.1016\/j.clbc.2026.06.012_bib0002","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1158\/0008-5472.CAN-16-1813","article-title":"Master transcriptional regulators in cancer: discovery via reverse engineering approaches and subsequent validation","volume":"77","author":"Moran","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.clbc.2026.06.012_bib0003","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy270.199","article-title":"Analytical validation of OncoMasTR, a multigene test for predicting risk of distant recurrence in hormone receptor-positive early stage breast cancer","volume":"29","author":"Loughman","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2026.06.012_bib0004","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1200\/JCO.2019.37.15_suppl.535","article-title":"Additional prognostic value of OncoMasTR multigene prognostic signature to clinicopathological information in patients with HR-positive, HER2-negative, lymph node-negative breast cancer from the TAILORx Tissue Bank, Ireland","volume":"37","author":"O'Connor","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2026.06.012_bib0005","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1158\/1078-0432.CCR-19-0712","article-title":"Validation of the OncoMasTR risk score in estrogen receptor-positive\/HER2-negative patients: a TransATAC study","volume":"26","author":"Buus","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2026.06.012_bib0006","doi-asserted-by":"crossref","first-page":"5931","DOI":"10.1158\/1078-0432.CCR-21-1023","article-title":"The OncoMasTR test predicts distant recurrence in estrogen receptor-positive, HER2-negative early breast cancer: a validation study in ABCSG Trial 8","volume":"27","author":"Filipits","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2026.06.012_bib0007","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0140-6736(05)67059-6","article-title":"Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years\u2019 adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial","volume":"366","author":"Jakesz","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2026.06.012_bib0008","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1200\/JCO.2011.36.8993","article-title":"Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group","volume":"30","author":"Dubsky","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2026.06.012_bib0009","doi-asserted-by":"crossref","first-page":"6012","DOI":"10.1158\/1078-0432.CCR-11-0926","article-title":"A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors","volume":"17","author":"Filipits","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2026.06.012_bib0010","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/annonc\/mdt494","article-title":"Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 risk of recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone","volume":"25","author":"Gnant","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2026.06.012_bib0011","doi-asserted-by":"crossref","first-page":"7828","DOI":"10.1158\/1078-0432.CCR-11-1846","article-title":"Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer","volume":"17","author":"Bago-Horvath","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2026.06.012_bib0012","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1158\/1078-0432.CCR-13-1845","article-title":"The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer","volume":"20","author":"Filipits","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2026.06.012_bib0013","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1158\/1078-0432.CCR-19-0376","article-title":"Prediction of distant recurrence using EndoPredict among women with ER(+), HER2(\u2212) node-positive and node-negative breast cancer treated with endocrine therapy only","volume":"25","author":"Filipits","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2026.06.012_bib0014","article-title":"A clinical validation study of MammaPrint in hormone receptor-positive breast cancer from the Austrian Breast and Colorectal Cancer Study Group 8 (ABCSG-8) biomarker cohort","volume":"6","author":"Dubsky","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.clbc.2026.06.012_bib0015","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1158\/1078-0432.CCR-20-0260","article-title":"Prognostic value of EndoPredict in women with hormone receptor-positive, HER2-negative invasive lobular breast cancer","volume":"26","author":"Sestak","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2026.06.012_bib0016","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/sim.4780030207","article-title":"Regression modelling strategies for improved prognostic prediction","volume":"3","author":"Harrell","year":"1984","journal-title":"Stat Med"},{"key":"10.1016\/j.clbc.2026.06.012_bib0017","doi-asserted-by":"crossref","first-page":"9067","DOI":"10.1200\/JCO.2004.01.0454","article-title":"Reporting recommendations for tumor marker prognostic studies","volume":"23","author":"McShane","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2026.06.012_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100228","article-title":"ESR1, PGR, ERBB2 and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6","volume":"6","author":"Filipits","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.clbc.2026.06.012_bib0019","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s10549-018-4889-5","article-title":"Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC\/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform","volume":"172","author":"Wu","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2026.06.012_bib0020","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1056\/NEJMoa1510764","article-title":"Prospective validation of a 21-gene expression assay in breast cancer","volume":"373","author":"Sparano","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2026.06.012_bib0021","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa1602253","article-title":"70-Gene signature as an aid to treatment decisions in early-stage breast cancer","volume":"375","author":"Cardoso van't Veer","year":"2016","journal-title":"N Engl J Med"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926000960?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926000960?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T23:31:21Z","timestamp":1786145481000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820926000960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1526820926000960"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2026.06.012","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Xpert Breast Cancer Insight Test Predicts Distant Recurrence and Overall Survival in ER-Positive, HER2-Negative Early Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2026.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}